The Longitude Prize series from Challenge Works will launch the Longitude Prize on amyotrophic lateral sclerosis (ALS) in Spring 2025. The next installment in the prize series follows the success of the Longitude Prize on antimicrobial resistance (AMR), won in 2024 by Sysmex Astrego’s PA-100 AST system, and the Longitude… Read More
SandboxAQ today announced a round of more than $300 million, which valued the company at $5.3 billion on a pre-money basis. The money came from investors Fred Alger Management, T Rowe Price Associates, Mumtalakat, Parkway Venture Capital, Breyer Capital, Rizvi Traverse, S32, US Innovative Technology Fund,… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
The Student Poster Award finalists for SLAS2025, taking place in San Diego, US, from 25-29 January 2025, have been confirmed. Visit these next-gen scientists working with cutting-edge automation to accelerate their discoveries and meet the future of the industry. Lan Mi, Graduate Student (University of Massachusetts, Amherst) Mi is presenting… Read More
Cradle, an AI-powered platform for protein engineering, has raised $73m in Series B funding to respond to rising demand in R&D intensive industries. This funding takes the total raised to date over $100m. The round was led by IVP with participation from previous investors Index Ventures and Kindred Capital. Proteins… Read More
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds. It can take years, and cost billions, to get new drugs approved for clinical use, but technological… Read More
BenevolentAI has unveiled a major strategic overhaul, which it says will return the company to its founding TechBio mission. The company has initiated significant organisational and budgetary changes that extend into 2027 and is also exploring options to delist from Euronext Amsterdam. Kenneth Mulvany, Executive… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all shine a light on… Read More
News round-up for 2-6 December by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all shine a light on innovation within drug discovery, including a potential ‘best-in-industry’ weight loss drug, a gold-based compound that shrinks tumours by 82%, and a second-generation CAR-T therapy. Read More
Another high profile speaker has signed up to the DDW SLAS track – Nicola Richmond, Chief Scientist, AI, Recursion. Nicola Richmond Richmond will be speaking at DDW‘s track – Concept to Cure: Curiosity and Lab Automation in Drug Discovery at SLAS2025 (25-29 January 2025, San… Read More
Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. The new funding will be used to accelerate the company’s growth and support the launch of two new commercial products,… Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA) approaches fall… Read More
The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ENV-294 targeting atopic dermatitis and other inflammatory conditions. A Phase I clinical trial has since started for ENV-294, with the first patient dosed at the end of October. Read More
Jason Park, Ph.D, CEO & Co-Founder of Empress Therapeutics and Operating Partner, Flagship Pioneering, examines why technologies such as artificial intelligence (AI) and machine learning (ML) will prove essential… Read More
Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More
Dr Raminderpal Singh, Global Head of AI & GenAI Practice, 20/15 Visioneers, will be speaking at DDW‘s track – Concept to Cure: Curiosity and Lab Automation in Drug Discovery – at SLAS2025 (25-29 January 2025, San Diego, USA). This free programme will present examples of… Read More
